Compounds > ziprasidone
Page last updated: 2024-08-24

ziprasidone and amphetamine

ziprasidone has been researched along with amphetamine in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's2 (40.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM1
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Guanowsky, V; Howard, HR; Lebel, LA; Lowe, JA; McLean, S; Schmidt, AW; Schulz, DW; Seeger, TF; Seymour, PA; Zorn, SH1

Reviews

1 review(s) available for ziprasidone and amphetamine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

4 other study(ies) available for ziprasidone and amphetamine

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
    Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3

    Topics:

2008
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
    Bioorganic & medicinal chemistry letters, 2010, Dec-15, Volume: 20, Issue:24

    Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility

2010
Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    The Journal of pharmacology and experimental therapeutics, 1995, Volume: 275, Issue:1

    Topics: Adenylyl Cyclases; Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Biogenic Monoamines; Brain; Catalepsy; Cattle; CHO Cells; Choroid Plexus; Cricetinae; Cyclic AMP; Dopamine Antagonists; Guinea Pigs; Humans; Male; Mice; Mice, Inbred Strains; Motor Activity; Neurotransmitter Uptake Inhibitors; Piperazines; Quipazine; Rats; Receptors, Adrenergic; Receptors, Dopamine; Receptors, Serotonin; Serotonin Antagonists; Swine; Thiazoles

1995